POINT Biopharma Global Inc. (NASDAQ:PNT) Receives $26.60 Average Target Price from Analysts

POINT Biopharma Global Inc. (NASDAQ:PNTGet Rating) has been given an average recommendation of “Hold” by the seven ratings firms that are presently covering the stock, MarketBeat reports. Two investment analysts have rated the stock with a sell rating and four have issued a buy rating on the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $29.00.

A number of brokerages have weighed in on PNT. Piper Sandler dropped their target price on shares of POINT Biopharma Global from $17.00 to $14.00 and set a “na” rating on the stock in a report on Friday, May 13th. Jefferies Financial Group raised shares of POINT Biopharma Global from a “hold” rating to a “buy” rating and increased their target price for the stock from $7.00 to $20.00 in a report on Thursday. Finally, Zacks Investment Research cut shares of POINT Biopharma Global from a “hold” rating to a “sell” rating in a report on Tuesday, March 29th.

NASDAQ PNT opened at $8.12 on Wednesday. POINT Biopharma Global has a 12 month low of $4.25 and a 12 month high of $11.72. The company has a market capitalization of $731.81 million, a price-to-earnings ratio of -11.94 and a beta of -0.39. The company’s fifty day moving average price is $7.73 and its two-hundred day moving average price is $6.97.

POINT Biopharma Global (NASDAQ:PNTGet Rating) last issued its earnings results on Friday, May 13th. The company reported ($0.18) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.03. As a group, research analysts predict that POINT Biopharma Global will post -1.06 EPS for the current fiscal year.

In other POINT Biopharma Global news, insider Neil E. Fleshner sold 564,204 shares of the firm’s stock in a transaction dated Wednesday, May 25th. The shares were sold at an average price of $7.51, for a total value of $4,237,172.04. Following the completion of the transaction, the insider now directly owns 3,023,045 shares in the company, valued at $22,703,067.95. The sale was disclosed in a filing with the SEC, which is accessible through this link.

Hedge funds have recently bought and sold shares of the stock. Morgan Stanley bought a new position in POINT Biopharma Global during the third quarter valued at approximately $27,000. Cubist Systematic Strategies LLC bought a new position in POINT Biopharma Global during the third quarter valued at approximately $28,000. Penserra Capital Management LLC bought a new position in POINT Biopharma Global during the fourth quarter valued at approximately $25,000. Marshall Wace LLP bought a new position in POINT Biopharma Global during the fourth quarter valued at approximately $27,000. Finally, Legal & General Group Plc bought a new position in POINT Biopharma Global during the fourth quarter valued at approximately $38,000. Institutional investors and hedge funds own 41.76% of the company’s stock.

POINT Biopharma Global Company Profile (Get Rating)

POINT Biopharma Global Inc, a late-stage clinical precision oncology company, focuses on the development and commercialization of radiopharmaceuticals for the treatment of cancer. Its lead product candidates include PNT2002, a prostate-specific membrane antigen (PSMA) targeted radioligand that is in Phase III trial for the treatment of metastatic castration-resistant prostate cancer; and PNT2003, a somatostatin-targeted radioligand, which is in Phase III trial for the treatment of neuroendocrine tumors.

Recommended Stories

Analyst Recommendations for POINT Biopharma Global (NASDAQ:PNT)

Receive News & Ratings for POINT Biopharma Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for POINT Biopharma Global and related companies with MarketBeat.com's FREE daily email newsletter.